1. Home
  2. EZGO vs OGEN Comparison

EZGO vs OGEN Comparison

Compare EZGO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZGO Technologies Ltd.

EZGO

EZGO Technologies Ltd.

HOLD

Current Price

$0.84

Market Cap

2.4M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.50

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZGO
OGEN
Founded
2014
1996
Country
China
United States
Employees
N/A
3
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.3M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
EZGO
OGEN
Price
$0.84
$0.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.0K
26.8K
Earning Date
07-01-2025
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.48
52 Week High
$3.30
$1.45

Technical Indicators

Market Signals
Indicator
EZGO
OGEN
Relative Strength Index (RSI) 44.30 43.89
Support Level $0.87 $0.49
Resistance Level $1.31 $0.59
Average True Range (ATR) 0.06 0.02
MACD 0.00 0.00
Stochastic Oscillator 46.03 33.92

Price Performance

Historical Comparison
EZGO
OGEN

About EZGO EZGO Technologies Ltd.

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: